iX Biopharma Ltd. (SGX: 42C)
Singapore
· Delayed Price · Currency is SGD
0.0240
0.00 (0.00%)
At close: Nov 20, 2024
iX Biopharma Balance Sheet
Financials in millions SGD. Fiscal year is July - June.
Millions SGD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
Cash & Equivalents | 1.77 | 1.77 | 6.52 | 13.49 | 6.21 | 5.66 | Upgrade
|
Short-Term Investments | 0.07 | 0.07 | 0.02 | 0.09 | 0.01 | 0.09 | Upgrade
|
Cash & Short-Term Investments | 1.84 | 1.84 | 6.53 | 13.59 | 6.21 | 5.75 | Upgrade
|
Cash Growth | -71.79% | -71.79% | -51.91% | 118.65% | 8.03% | -63.83% | Upgrade
|
Accounts Receivable | 1.29 | 1.29 | 1.25 | 0.5 | 0.22 | 0.15 | Upgrade
|
Other Receivables | 1.63 | 1.63 | 1.8 | 1.48 | 1.59 | 1.15 | Upgrade
|
Receivables | 2.92 | 2.92 | 3.05 | 1.98 | 1.82 | 1.3 | Upgrade
|
Inventory | 1.38 | 1.38 | 0.96 | 0.91 | 1.1 | 0.88 | Upgrade
|
Prepaid Expenses | 0.44 | 0.44 | 0.44 | 0.37 | 0.22 | 0.21 | Upgrade
|
Total Current Assets | 6.59 | 6.59 | 10.98 | 16.84 | 9.35 | 8.14 | Upgrade
|
Property, Plant & Equipment | 7.61 | 7.61 | 8.22 | 7.72 | 8.95 | 8.29 | Upgrade
|
Long-Term Investments | 0.01 | 0.01 | 3.87 | 2.26 | - | - | Upgrade
|
Goodwill | 0.29 | 0.29 | 0.29 | 0.31 | 0.33 | 0.31 | Upgrade
|
Other Intangible Assets | 0 | 0 | - | 0.04 | 0.09 | 0.14 | Upgrade
|
Long-Term Deferred Tax Assets | - | - | 1.38 | 1.28 | - | - | Upgrade
|
Other Long-Term Assets | 0.13 | 0.13 | 0.19 | 0.07 | 0.15 | 0.11 | Upgrade
|
Total Assets | 14.62 | 14.62 | 24.93 | 28.52 | 18.86 | 16.98 | Upgrade
|
Accounts Payable | 1.26 | 1.26 | 0.4 | 0.22 | 0.55 | 0.85 | Upgrade
|
Accrued Expenses | 2.87 | 2.87 | 2.81 | 2.31 | 2.31 | 1.97 | Upgrade
|
Current Portion of Long-Term Debt | 2.49 | 2.49 | 2.75 | 3.29 | 0.42 | 0.22 | Upgrade
|
Current Portion of Leases | 0.39 | 0.39 | 0.44 | 0.24 | 0.38 | 0.25 | Upgrade
|
Current Income Taxes Payable | 0.17 | 0.17 | 0.73 | 1.76 | - | - | Upgrade
|
Other Current Liabilities | 0.21 | 0.21 | 0.05 | 0.04 | 0.02 | 0.02 | Upgrade
|
Total Current Liabilities | 7.38 | 7.38 | 7.18 | 7.86 | 3.67 | 3.3 | Upgrade
|
Long-Term Debt | 2.18 | 2.18 | 0.57 | 0.88 | 3.2 | 3.44 | Upgrade
|
Long-Term Leases | 0.14 | 0.14 | 0.58 | - | 0.24 | 0.02 | Upgrade
|
Other Long-Term Liabilities | 0.58 | 0.58 | 0.76 | 0.04 | 0.04 | 0.06 | Upgrade
|
Total Liabilities | 10.28 | 10.28 | 9.08 | 8.77 | 7.15 | 6.81 | Upgrade
|
Common Stock | 97.45 | 97.45 | 97.23 | 94.18 | 83.34 | 72.25 | Upgrade
|
Retained Earnings | -96.98 | -96.98 | -86.18 | -76.57 | -71.97 | -63.74 | Upgrade
|
Comprehensive Income & Other | 3.87 | 3.87 | 4.8 | 2.13 | 0.34 | 1.65 | Upgrade
|
Shareholders' Equity | 4.34 | 4.34 | 15.85 | 19.74 | 11.71 | 10.17 | Upgrade
|
Total Liabilities & Equity | 14.62 | 14.62 | 24.93 | 28.52 | 18.86 | 16.98 | Upgrade
|
Total Debt | 5.2 | 5.2 | 4.34 | 4.41 | 4.24 | 3.92 | Upgrade
|
Net Cash (Debt) | -3.36 | -3.36 | 2.2 | 9.18 | 1.98 | 1.83 | Upgrade
|
Net Cash Growth | - | - | -76.08% | 363.97% | 7.91% | -84.81% | Upgrade
|
Net Cash Per Share | -0.00 | -0.00 | 0.00 | 0.01 | 0.00 | 0.00 | Upgrade
|
Filing Date Shares Outstanding | 883.34 | 883.34 | 766.3 | 764.9 | 746.17 | 648.89 | Upgrade
|
Total Common Shares Outstanding | 768.32 | 768.32 | 766.3 | 751.19 | 697.35 | 648.89 | Upgrade
|
Working Capital | -0.8 | -0.8 | 3.8 | 8.99 | 5.68 | 4.85 | Upgrade
|
Book Value Per Share | 0.01 | 0.01 | 0.02 | 0.03 | 0.02 | 0.02 | Upgrade
|
Tangible Book Value | 4.05 | 4.05 | 15.56 | 19.4 | 11.3 | 9.72 | Upgrade
|
Tangible Book Value Per Share | 0.01 | 0.01 | 0.02 | 0.03 | 0.02 | 0.01 | Upgrade
|
Land | 2.57 | 2.57 | 2.56 | 2.73 | 2.88 | 2.73 | Upgrade
|
Buildings | 1.74 | 1.74 | 1.74 | 1.85 | 1.97 | 1.85 | Upgrade
|
Machinery | 6.99 | 6.99 | 6.71 | 6.6 | 7.13 | 6.3 | Upgrade
|
Leasehold Improvements | 0.76 | 0.76 | 0.74 | 0.64 | 0.25 | 0.24 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.